Skip to main content
. 2018 Dec 20;39:173–181. doi: 10.1016/j.ebiom.2018.12.013

Fig. 4.

Fig. 4

Infusion of anti-CD19 CAR T cells results in a rapid decrease in normal human B cells. (A) Levels (%) of human CD19+GFP− B cells in PBMCs at the indicated times after infusion of 19/28z (n = 7) or control (4H11/28z; n = 5) CAR T cells. (B) Representative FACS profiles for human CD19+ (GFP−) B cells in PBMCs (at week 1) from anti-CD19 CAR or control T cell-treated leukemic hu-mice. (C) Correlation between the level (%) of anti-CD19 CAR T cells at week 4 and the levels (%) of normal human CD19+GFP− B cells at weeks 1 (Left) and 4 (Right) after infusion of anti-CD19 (19/28z) CAR T cells (each symbol represents an individual mouse). The data shown are from one of three independent experiments with similar results.